Page last updated: 2024-10-23

aspirin and Embryopathies

aspirin has been researched along with Embryopathies in 21 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

ExcerptRelevanceReference
"Indications for aspirin during pregnancy are a matter of debate and there is a recent trend to an extended prescription and an overuse of aspirin in pregnancy."9.01[Aspirin and preeclampsia]. ( Atallah, A; Doret-Dion, M; Gaucherand, P; Goffinet, F; Lecarpentier, E; Tsatsaris, V, 2019)
"Self-reported use or consumption of tobacco, marijuana, cocaine, aspirin, and other nonsteroidal antiinflammatory drugs during pregnancy."7.69Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. ( Allred, EN; Cohen, A; Epstein, MF; Leviton, A; Pagano, M; Sullivan, KF; Van Marter, LJ, 1996)
"Indications for aspirin during pregnancy are a matter of debate and there is a recent trend to an extended prescription and an overuse of aspirin in pregnancy."5.01[Aspirin and preeclampsia]. ( Atallah, A; Doret-Dion, M; Gaucherand, P; Goffinet, F; Lecarpentier, E; Tsatsaris, V, 2019)
"The aim of this study was to evaluate whether low doses of aspirin (100 mg per day) administered to a homogeneous population of women early (8-10 weeks) during their first pregnancy improved the outcome of gestation hypertensive disorders."3.77Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. ( Bakhti, A; Vaiman, D, 2011)
"The prevention of preeclampsia currently relies on low-dose aspirin started at the beginning of pregnancy."3.72[Prevention of preeclampsia]. ( Desvaux, D; Haddad, B, 2003)
"Self-reported use or consumption of tobacco, marijuana, cocaine, aspirin, and other nonsteroidal antiinflammatory drugs during pregnancy."3.69Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. ( Allred, EN; Cohen, A; Epstein, MF; Leviton, A; Pagano, M; Sullivan, KF; Van Marter, LJ, 1996)
"Over-the-counter antipyretics (acetaminophen, aspirin, ibuprofen) and/or analgesics (acetaminophen, aspirin, diclofenac, ibuprofen, naproxen) are relatively safe for adults."2.48[Developmental toxicity of the over-the-counter analgetics and antypiretics]. ( Burdan, F; Cendrowska-Pinkosz, M; Dworzańska, A; Dworzański, W; Kubiatowski, T; Starosławska, E; Szumiło, J; Urbańczyk-Zawadzka, M, 2012)
"If diagnosed and treated early in pregnancy with low-dose aspirin and subcutaneous heparin the outlook for a successful pregnancy is much improved."2.41A literature review on the antiphospholipid syndrome and the effect on childbearing. ( Vials, JM, 2001)
"We estimated the proportion of miscarriage to be almost doubled, whereas there was no increased risk of congenital abnormalities or prematurity in women exposed to a drug overdose compared with the background population."1.31Pregnancy outcome after suicide attempt by drug use: a Danish population-based study. ( Flint, C; Larsen, H; Nielsen, GL; Olsen, J; Sørensen, HT, 2002)

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19906 (28.57)18.7374
1990's5 (23.81)18.2507
2000's7 (33.33)29.6817
2010's3 (14.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Atallah, A1
Lecarpentier, E1
Goffinet, F2
Gaucherand, P1
Doret-Dion, M1
Tsatsaris, V1
Bakhti, A1
Vaiman, D1
Burdan, F1
Starosławska, E1
Szumiło, J1
Dworzańska, A1
Dworzański, W1
Kubiatowski, T1
Cendrowska-Pinkosz, M1
Urbańczyk-Zawadzka, M1
PETROV-MASLAKOV, MA1
Desvaux, D1
Haddad, B1
Nitsch, P1
Breuer, J1
Geipel, A1
Bartmann, P1
Gembruch, U1
Heep, A1
Iwashita, T1
Fujitani, M1
Yamamoto, Y1
Katsurada, T1
Yoshida, Y1
Aguilera, C1
Agustí, A1
Srivastava, AR1
Modi, P1
Sahi, S1
Niwariya, Y1
Singh, H1
Banerjee, A1
Soller, RW1
Stander, H1
Van Marter, LJ1
Leviton, A1
Allred, EN1
Pagano, M1
Sullivan, KF1
Cohen, A1
Epstein, MF1
Bréart, G1
Uzan, S1
Wakatsuki, A1
Izumiya, C1
Okatani, Y1
Sagara, Y1
Vials, JM1
Flint, C1
Larsen, H1
Nielsen, GL1
Olsen, J1
Sørensen, HT1
Ginsberg, JS1
Hirsh, J1
Raub, W1
Lubbe, WF1
Liggins, GC1
Wilson, JG1
Fisch, L1
Warkany, J1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680]11,976 participants (Actual)Interventional2016-03-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Fetal Outcome 1 - Incidence of Early Preterm Delivery (<34 Weeks)

- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm189
Placebo Arm230

Fetal Outcome 2 - Incidence of Actual Birth Weight <2500g

- Birth weight <2500g (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm1078
Placebo Arm1153

Fetal Outcome 3 - Incidence of Actual Birth Weight <1500g

- Birth weight <1500g (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm78
Placebo Arm101

Fetal Outcome 4 - Incidence of Fetal Loss

- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm303
Placebo Arm353

Fetal Outcome 5 - Incidence of Spontaneous Abortion

- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm134
Placebo Arm152

Fetal Outcome 6 - Incidence of All Stillbirth

- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm141
Placebo Arm166

Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy

- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm42
Placebo Arm30

Incidence of Hypertensive Disorders of Pregnancy

- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)

InterventionParticipants (Count of Participants)
Intervention Arm352
Placebo Arm325

Incidence of Perinatal Mortality

- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm264
Placebo Arm309

Incidence of Preterm Birth

The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm668
Placebo Arm754

Incidence of Small for Gestational Age (SGA)

- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm1506
Placebo Arm1564

Maternal Outcome 1 - Incidence of Vaginal Bleeding

- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm214
Placebo Arm246

Maternal Outcome 2 - Incidence of Antepartum Hemorrhage

- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm26
Placebo Arm25

Maternal Outcome 3 - Incidence of Postpartum Hemorrhage

- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm54
Placebo Arm43

Maternal Outcome 4 - Incidence of Maternal Mortality

- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm9
Placebo Arm12

Maternal Outcome 5 - Incidence of Late Abortion

- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm23
Placebo Arm30

Maternal Outcome 6 - Change in Maternal Hemoglobin

Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.

InterventionParticipants (Count of Participants)
Intervention Arm290
Placebo Arm333

Maternal Outcome 7 - Incidence of Preterm, Preeclampsia

Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm8
Placebo Arm21

Reviews

7 reviews available for aspirin and Embryopathies

ArticleYear
[Aspirin and preeclampsia].
    Presse medicale (Paris, France : 1983), 2019, Volume: 48, Issue:1 Pt 1

    Topics: Aspirin; Chronobiology Phenomena; Contraindications, Drug; Cyclooxygenase Inhibitors; Drug Utilizati

2019
[Developmental toxicity of the over-the-counter analgetics and antypiretics].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2012, Volume: 32, Issue:192

    Topics: Adult; Analgesics; Antipyretics; Aspirin; Female; Fetal Diseases; Humans; Infant, Newborn; Infant, N

2012
Anticoagulation for pregnant patients with mechanical heart valves.
    Annals of cardiac anaesthesia, 2007, Volume: 10, Issue:2

    Topics: Abortion, Spontaneous; Anticoagulants; Aspirin; Drug Administration Schedule; Female; Fetal Diseases

2007
A literature review on the antiphospholipid syndrome and the effect on childbearing.
    Midwifery, 2001, Volume: 17, Issue:2

    Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Embolism; Female; Fetal Death; Fetal Diseases; F

2001
Use of antithrombotic agents during pregnancy.
    Chest, 1992, Volume: 102, Issue:4 Suppl

    Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fetal Diseases; Hemorrhage; Humans; Oste

1992
Lupus anticoagulant and pregnancy.
    American journal of obstetrics and gynecology, 1985, Oct-01, Volume: 153, Issue:3

    Topics: Aspirin; Autoantibodies; Blood Coagulation Factors; Female; Fetal Death; Fetal Diseases; Fetal Growt

1985
Present status of drugs as teratogens in man.
    Teratology, 1973, Volume: 7, Issue:1

    Topics: Abnormalities, Drug-Induced; Alkylating Agents; Anti-Bacterial Agents; Anticonvulsants; Antiemetics;

1973

Other Studies

14 other studies available for aspirin and Embryopathies

ArticleYear
Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2011, Volume: 34, Issue:10

    Topics: Adult; Aspirin; Birth Weight; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Fetal

2011
[PRENATAL PROTECTION OF THE FETUS AND PROBLEMS OF DRUG THERAPY IN PREGNANCY].
    Sovetskaia meditsina, 1964, Volume: 28

    Topics: Adrenal Cortex Hormones; Aminopyrine; Anti-Bacterial Agents; Aspirin; Drug Therapy; Female; Fetal Di

1964
[Prevention of preeclampsia].
    Presse medicale (Paris, France : 1983), 2003, Oct-11, Volume: 32, Issue:33

    Topics: Adult; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fetal Diseas

2003
Dilatation of the abdominal umbilical vein is associated with increased risk of thrombotic complications.
    Journal of perinatal medicine, 2006, Volume: 34, Issue:3

    Topics: Abdomen; Adult; Aspirin; Dilatation, Pathologic; Female; Fetal Diseases; Fibrinolytic Agents; Hepari

2006
Interferon-alfa treatment of essential thrombocythemia during pregnancy.
    Internal medicine (Tokyo, Japan), 2006, Volume: 45, Issue:20

    Topics: Adult; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Fetal Diseases; Humans; Immunolog

2006
[Low dose of aspirin during pregnancy].
    Medicina clinica, 2007, Jan-13, Volume: 128, Issue:1

    Topics: Abnormalities, Drug-Induced; Abortion, Habitual; Abortion, Spontaneous; Adult; Animals; Anti-Inflamm

2007
Maternal drug exposure and perinatal intracranial hemorrhage.
    Obstetrics and gynecology, 1981, Volume: 58, Issue:6

    Topics: Aspirin; Cerebral Hemorrhage; Female; Fetal Diseases; Humans; Infant, Newborn; Infant, Newborn, Dise

1981
Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy.
    Pediatrics, 1996, Volume: 97, Issue:5

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cocaine; Confounding

1996
ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women.
    British journal of obstetrics and gynaecology, 1996, Volume: 103, Issue:7

    Topics: Aspirin; Female; Fetal Diseases; Humans; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Compl

1996
Oxidative damage in fetal rat brain induced by ischemia and subsequent reperfusion. Relation to arachidonic acid peroxidation.
    Biology of the neonate, 1999, Volume: 76, Issue:2

    Topics: Animals; Arachidonic Acid; Aspirin; Brain; Cyclooxygenase Inhibitors; Disease Models, Animal; Female

1999
Pregnancy outcome after suicide attempt by drug use: a Danish population-based study.
    Acta obstetricia et gynecologica Scandinavica, 2002, Volume: 81, Issue:6

    Topics: Abortion, Spontaneous; Acetaminophen; Adolescent; Adult; Aspirin; Child; Child, Preschool; Denmark;

2002
From the National Institutes of Health.
    JAMA, 1990, Mar-02, Volume: 263, Issue:9

    Topics: Aspirin; Breast Neoplasms; Female; Fetal Diseases; Heart Defects, Congenital; Humans; Immunotherapy;

1990
The selective and differential vulnerability of the auditory system. In: Sensorineural hearing loss.
    Ciba Foundation symposium, 1970

    Topics: Aspirin; Auditory Pathways; Central Nervous System; Cochlea; Deafness; Diseases in Twins; Ear; Facia

1970
Experimental teratology and pediatrics.
    Paediatria Universitatis Tokyo, 1970, Volume: 18

    Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Congenital Abnormalities; Female; Fetal Diseases; Mam

1970